Liquid and Tissue Biopsy in the Treatment of NSCLC: Focus on MET Gene Aberrations - a podcast by ReachMD

CME credits: 0.25

Valid until: 23-04-2022

Claim your CME credit at https://reachmd.com/programs/cme/liquid-and-tissue-biopsy-treatment-nsclc-focus-met-gene-aberrations/12465/

Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD